Manta Pharma: Precision Drug Delivery Powered by AI

Manta Pharma LLC is a U.S.-based biotech startup revolutionizing drug delivery for chronic diseases through its AI-powered Active Implantable Medical Device (AIMD)—a patented drug/device combination platform that delivers medications with unparalleled precision, safety, and autonomy.

Our system integrates three key components: a body temperature–stable drug formulation, an intelligent micro-pump, and a biosensor—all coordinated by an AI engine that functions like an “autopilot,” adjusting drug delivery in real time based on patient needs.

We are initially targeting high-need conditions such as autoimmune diseases, diabetes, substance use disorders, and HIV/AIDS—areas where poor adherence remains a major barrier to effective treatment. Manta’s closed-loop, subcutaneous implant ensures reliable delivery of time-critical medications for a broad spectrum of chronic diseases—including diabetes, cardiovascular disease, autoimmune disorders, chronic lung diseases (such as COPD and asthma), chronic liver and kidney diseases, substance use disorders, HIV/AIDS, central nervous system (CNS) disorders, chronic pain, cancer, and neurodegenerative conditions like Alzheimer’s and Parkinson’s disease—whether at home, in hospitals or hospices, for senior citizens, during travel, or in high-stress environments such as military deployment.

With a rising global demand for smarter, longer-acting, and personalized therapies, Manta Pharma is positioned to lead the next wave of autonomous drug delivery innovation.

Manta Pharma’s AIMD platform is protected by a robust IP portfolio, with patents specifically covering the drug/device combination and extending through 2045 and beyond. We are actively seeking strategic partners to accelerate clinical development, strengthen our patent estate, and bring this transformative technology to patients worldwide.